{"entity":{"id":"nct05958121","kind":"trial","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IMA402 in advanced solid tumours, run by Immatics Biotechnologies GmbH, now recruiting.","summary":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT05958121 by Immatics Biotechnologies GmbH, with 400 participants planned, started 2023-08-09 and due to reach its primary completion in 2027-09. Interventions recorded: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody and IMA402 and chemotherapy +/- monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05958121","url":"https://clinicaltrials.gov/study/NCT05958121"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05958121","phase":"1/2","setting":"A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors","sponsor":"Immatics Biotechnologies GmbH","enrolled":400,"outcomes":[]},"route":"/trials/nct05958121/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}